Screenings such as mammography, detection of lung cancer through CT scans, or acetic acid visualisation of the cervix, along with age-appropriate physical activity, are proven methods of cancer prevention. However, people usually don’t prioritise healthcare. The only way to increase awareness is by educating them through audio-visual messages and the social media.
Screenings such as mammography, detection of lung cancer through CT scans, or acetic acid visualisation of the cervix, along with age-appropriate physical activity, are proven methods of cancer prevention. However, people usually don’t prioritise healthcare. The only way to increase awareness is by educating them through audio-visual messages and the social media.
A study in the US has found 3,000 times higher carcinogen content in anti-acidity drug ranitidine. But it’s business as usual in India. While GSK and Dr. Reddy’s have recalled the drug globally, Cadila Pharma and JB Chemicals say they will continue to sell it as their internal tests have shown that the presence of N-DMA in their products is within permissible limits.
Amid strong demands to lift the blanket price cap on stents and create room for innovation and research, the government is doing a balancing act on access and affordability with only a few having access to modern technology and fewer being able to afford it.
The Modi government will set up 75 medical colleges to bridge regional disparities in access to quality healthcare, but India needs structural reforms to build world-class institutes. The new National Medical Commission must find ways to plug systemic deficiencies, from an outdated curriculum to a faculty crunch.
Healthcare will be a dominant theme in developing India over the next few decades. But with a largely self-financed healthcare system, robust top-line growth will be a challenge for several hospital chains for a while. Indeed, future value for investors may be created more by capital and cost efficiencies and less through top-line growth.
The largely family-run Dr. Reddy’s Labs has brought in the former Teva executive to helm a company that has been going through a testing time. Starting off with a rejig of its product portfolio, Israeli plans to double down on growth in the home market, apart from the US, China, and Russia, and build a strong pipeline of innovative formulations.
Most Indian cardiac patients need to pop up to six pills to manage their condition. A recent medical study says a super-pill can help. Indian doctors have historically been unenthused by such a pill, but the benefits are too significant to ignore.
The undisputed leader in the northern, central, and eastern markets is bracing up for new rivalries.
Beijing has announced a raft of reforms for procuring generic drugs. This has renewed hope for Indian pharma companies, which in the last two decades had lost their hold on the Chinese market. Sluggish growth in India, the US, and Europe makes this newfound opportunity all the more attractive.
US biotechnology giant Amgen/Allergan has surprised Biocon/Mylan by launching a biosimilar of trastuzumab in the US. The move is a big jolt for Biocon/Mylan, as it was widely believed that they would launch first and gain an edge. Biocon, however, feels it has sufficient edge and stays unaffected.
